COC formulation | Number of studies | Before Md (1st – 3rd) | After Md (1st – 3rd) | ∆ | p* |
---|---|---|---|---|---|
Total Cholesterol (mg/dl) | |||||
 EE 35 μg / CPA 2 mg | 12 | 173.7 (162.1–184.1) | 189.0 (185.3–200.9) | +15.3 | 0.012 |
 EE 30 μg / DRSP 3 mg | 09 | 171.5 (166.8–185.9) | 185.2 (167.3–203.1) | 13.7 | 0.085 |
 EE 30 μg / DSG 75–150 μg | 03 | 158.9 (154.9–162.9) | 178.8 (169.0–188.4) | +19.5 | 0.108 |
 EE 30 μg / 180–250 μg NGM | 02 | 168.9 (167.6–170.2) | 181.7 (181.3–182.1) | +12.8 | 0.060 |
 EE 30 μg / 150 μg LNG | 02 | 161.8 (158.4–165.2) | 170.4 (169.1–173.8) | +8.6 | 0.265 |
LDL-C (mg/dl) | |||||
 EE 35 μg / CPA 2 mg | 11 | 98.0 (91.0–103.9) | 101.9 (86.8–114.6) | +3.9 | 0.241 |
 EE 30 μg / DRSP 3 mg | 08 | 95.2 (87.6–107.0) | 101.3 (92.6–113.1) | +6.1 | 0.345 |
 EE 30 μg / CMA 2 μg | 03 | 101.5 (99.6–103.4) | 100.9 (98.3–103.5) | +0.6 | 0.486 |
 EE 30 μg / DSG 75–150 μg | 03 | 94.3 (94.0–94.5) | 106.8 (100.9–112.7) | +12.5 | 0.108 |
 EE 30 μg / NGM 180–250 μg | 02 | 100.2 (99.9–100.5) | 107.6 (106.7–108.3) | +7.4 | 0.031 |
 EE 30 μg / LNG 150 μg | 02 | 87.2 (77.4–97.0) | 90.6 (80.2–101.0) | +3.4 | 0.022 |
HDL-C (mg/dl) | |||||
 EE 35 μg / CPA 2 mg | 10 | 54.3 (50.2–59.5) | 61.5 (60.7–67.2) | +7.3 | 0.020 |
 EE 30 μg / DRSP 3 mg | 08 | 59.5 (50.0–62.5) | 73.3 (64.5–79.7) | +13.8 | 0.017 |
 EE 30 μg / CMA 2 mg | 03 | 51.1 (49.9–52.3) | 61.4 (61.1–61.7) | +10.3 | 0.108 |
 EE 30 μg / DSG 75/150 μg | 03 | 49.6 (34.7–59.7) | 45.3 (26.0–75.0) | −3.3 | 0.592 |
TG (mg/dl) | |||||
 EE 35 μg / CPA 2 mg | 11 | 81.4 (69.0–99.1) | 104.0 (85.8–123.4) | +22.6 | 0.021 |
 EE 30 μg / DRSP 3 mg | 07 | 95.0 (72.8–105.6) | 116.8 (115.0–138.9) | +21.8 | 0.017 |
 EE 30 μg / CMA 2 mg | 03 | 83.9 (83.6–84.2) | 125.5 (116.1–134.9) | +41.6 | 0.108 |
 EE 30 μg / DSG 75–150 μg | 03 | 87.7 (83.7–91.7) | 108.3 (102.4–114.2) | +20.6 | 0.137 |
 EE 30 μg / NGM 180–250 μg | 03 | 104.7 (86.1–123.3) | 134.3 (117.4–151.3) | +29.6 | 0.025 |